Zhifei Secures Exclusive Rights to Distribute GSK’s Shingles Vaccine in China
The recent deal between China’s leading vaccine company, Zhifei, and British drugmaker GSK marks a significant move in Western pharmaceutical firms’ efforts to penetrate China’s pharmaceutical market. Valued at 2.5 billion pounds ($3.05 billion), this agreement grants Zhifei exclusive distribution rights for GSK’s top-selling shingles vaccine, Shingrix, in the second-largest pharmaceutical market globally.